Peptide conjugates modified n- and/or c-terminally by short charged peptide chains
CA 2410224 C · Owner: Zealand Pharma A/S · Inventors: Harlow, Kenneth William; Petersen, Jorgen Soberg; Kapusta, Daniel R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are a variety of peptide conjugates represented by the following general formula (I): R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula (II): A1-A2-A3-A4-A5-A6 wherein A1 represents Arg Lys, or His, A2 , represents Tyr, Trp, or Phe A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, Arg or His, A5 represents Phe, Tyr Trp, Leu, Val or Ile, and A6 , represents Arg Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged peptide chain of from 4 to 20 amino acid residues having …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 15, 2001 and granted August 13, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 15, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 15, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.